EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC0

Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication

Ibrahim O Sawaid, Zohar Din, Efrat Golan, Eytan Ruppin, Avivit Golan-Cohen, Ilan Green, Eugene Merzon, Shlomo Vinker, Abraham O Samson iD, Ariel Israel iD

PLOS Medicine · 06.01.2026 · 23 (1) · e1004842

DOI: 10.1371/journal.pmed.1004842 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift PLOS Medicine, online erschienen am 06.01.2026. Verfasst von Ibrahim O Sawaid und 9 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Gastrointestinal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Leumit Health Services, National Institute of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proton pump inhibitors (PPIs) are widely used for acid-related disorders, but observational studies have raised concerns about a possible association between long-term PPI use and upper gastrointestinal (GI) cancers. These associations may reflect confounding by indication and reverse causation. We aimed to evaluate the association between PPI use and upper GI cancer while explicitly addressing these biases. Methods and findings We conducted a matched case-control study using electronic health records from a national health organization in Israel. Cases were 875 adults (age 63.0 ± 11.9 years, 62.5% male) with incident upper GI cancer (esophageal, gastric, or duodenal) diagnosed between 2003 and 2024; each case was matched to 10 cancer-free controls ( n = 8,750). Matching was performed on age, sex, ethnic sector (general, Jewish ultra-orthodox, and Arab), socioeconomic status, and year of enrollment. PPI exposure was ascertained from pharmacy records and modeled in discrete pre-diagnosis windows (0–6 months, 6–12 months, 1–3 years, and 3–10 years). Multivariable conditional logistic regression estimated adjusted odds ratios (aORs) and confidence intervals (CIs), with covariates including age, smoking, body mass index, socioeconomic status, healthcare utilization, pregnancy history (in women), alcohol use, Helicobacter pylori diagnosis, and upper GI symptom-related diagnoses (e.g., gastroesophageal reflux, gastritis, peptic ulcer disease). In models without adjustment for symptom-related diagnoses, PPI use was associated with increased odds of cancer (e.g., esomeprazole aOR 4.01, 95% CI 3.20, 5.03, p < 0.001; omeprazole aOR 2.38, 95% CI 1.99, 2.85, p < 0.001). When exposure was modeled by time window, associations diminished for exposures >1 year before diagnosis. After excluding the final year before diagnosis and adjusting for symptom-related diagnoses, we did not detect a harmful association between PPI use and upper GI cancer. Remote use (>3 years) was instead associated with lower odds (e.g., omeprazole aOR 0.62, 95% CI 0.51, 0.75, p < 0.001), with similar patterns in a gastric-only subgroup (701 cases, 7,010 controls). Key limitations include potential residual confounding, lack of direct dietary and family-history data, and incomplete capture of over-the-counter PPI use.

Conclusions

Apparent harmful associations between PPI use and upper GI cancer were concentrated in the months immediately preceding diagnosis and disappeared after adjusting for diagnostic context and excluding the final year before diagnosis. In these adjusted analyses, we found no evidence of increased odds with long-term PPI use, and remote use (>3 years before diagnosis) was associated with reduced cancer odds for omeprazole and lansoprazole. These findings underscore the importance of investigating new-onset upper GI symptoms rather than attributing malignancy risk to acid-suppressive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsGastrointestinal NeoplasmsHumansFemaleMaleMiddle AgedCase-Control StudiesAgedIsraelRisk FactorsConfounding Factors, EpidemiologicElectronic Health Records

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Drug Discovery Lab, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
  • Department of Family Medicine and Leumit Research Institute, Leumit Health Services, Tel-Aviv, Israel.
  • Pediatric Intensive Care Unit, Haemek Medical Center, Afula, Israel.
  • Cancer Data Science Laboratory, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Translational Research Institute and the Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.
  • Department of Family Medicine, Grey Faculty of Medical & Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.

ORCID-Profile: Abraham O Samson, Ariel Israel

Förderung

  • Leumit Health Services
  • National Institute of Health, National Cancer Institute

Zitieren

APA

Sawaid, I. O., Din, Z., Golan, E., Ruppin, E., Golan-Cohen, A., Green, I., Merzon, E., Vinker, S., Samson, A. O., & Israel, A. (2026). Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication. PLOS Medicine, 23(1), e1004842. https://doi.org/10.1371/journal.pmed.1004842

Vancouver

Sawaid IO, Din Z, Golan E, Ruppin E, Golan-Cohen A, Green I, et al. Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication. PLOS Medicine. 2026;23(1):e1004842. doi:10.1371/journal.pmed.1004842

BibTeX
@article{Sawaid2026,
  author = {Sawaid, Ibrahim O and Din, Zohar and Golan, Efrat and Ruppin, Eytan and Golan-Cohen, Avivit and Green, Ilan and Merzon, Eugene and Vinker, Shlomo and Samson, Abraham O and Israel, Ariel},
  title = {Association between proton pump inhibitor use and upper gastrointestinal cancer: A matched case-control study accounting for reverse causation and confounding by indication},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {1},
  pages = {e1004842},
  doi = {10.1371/journal.pmed.1004842}
}
Kostenlos starten →